Publications

Publications, Books, Book Chapters and Reviews by Prof. Marcus Maurer, MD

Use: Start with an overview of all publications. Use tag links to list selected documents or to list an entire category, e.g. Original Work, Books, Book Chapters, Reviews. If you know what you are looking for, enter this term in the search field.

Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyreoperoxidase

Filename 114. Maurer et al., Efficacy and safety of omalizumab, JACI 2011.pdf
Filesize 586.46 KB
Version o.114
Date added May 30, 2020
Downloaded 4 times
Category Original Work
Authors Maurer, M., Altrichter, S., Bieber, T., Biedermann, T., Bräutigam, M., Seyfried, S, Brehler, R., Grabbe, J., Hunzelmann, N., Jakob, T., Jung, A., Kleine-Tebbe, J., Mempel, M., Meurer, M., Reich, K., Ruëff, F., Sengupta, K., Sieder, C., Simon, J. C., Wedi, B., Zuberbier, T., Mahler, V., and Staubach, P.
Citation Maurer, M., Altrichter, S., Bieber, T., Biedermann, T., Bräutigam, M., Seyfried, S, Brehler, R., Grabbe, J., Hunzelmann, N., Jakob, T., Jung, A., Kleine-Tebbe, J., Mempel, M., Meurer, M., Reich, K., Ruëff, F., Sengupta, K., Sieder, C., Simon, J. C., Wedi, B., Zuberbier, T., Mahler, V., and Staubach, P.: Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyreoperoxidase. J. Allergy Clin. Immunol. 2011: 128; 202-209.
Corresponding authors Maurer, M.
DocNum o.114
DocType PDF
Edition; Page 128; 202-209.
IF 11.00
Publisher J. Allergy Clin. Immunol.
ReleaseDate 2011

Background: A subgroup of patients with chronic spontaneous urticaria (CU) exhibits IgE antibodies directed against autoantigens, such as thyroperoxidase (TPO). We conducted
this study to investigate whether such patients with CU with IgE against TPO benefit from treatment with omalizumab, a humanized anti-IgE mAb licensed for the treatment of severe persistent allergic (IgE-mediated) asthma.

Objectives: We sought to assess the efficacy of omalizumab treatment in patients with CU with IgE autoantibodies against TPO.

Methods: In this multicenter, randomized, double-blind, placebo-controlled study patients with CU (male/female, 18-70 years of age) with IgE autoantibodies against TPO who had persistent symptoms (wheals and pruritus) despite standard antihistamine therapy were randomized to receive either omalizumab (75-375 mg, dose determined by using the approved asthma dosing table) or placebo subcutaneously once every 2 or 4 weeks for 24 weeks. The primary end point was the change from baseline in mean weekly urticaria activity score after 24 weeks of treatment, as calculated from patients’ diaries. The safety and tolerability of omalizumab were also assessed.

Results: Of the 49 randomized patients (omalizumab, n 5 27;placebo, n 5 22), 42 completed the study. At week 24, patients demonstrated a mean reduction in the weekly urticaria activity
score from baseline of 17.8 with omalizumab and 7.9 with placebo (P 5 .0089). Complete protection from wheal development was observed in 19 (70.4%) patients in the omalizumab group
compared with only 1 (4.5%) patient in the placebo group. The rate of adverse events was similar in both groups.

Conclusions: The results of this study indicate that omalizumab is an effective treatment option for patients with CU with IgE autoantibodies against TPO who are refractory to conventional
treatment.

 

(Last update: 12.2023)

Number of original publications in peer-reviewed journals:580
Number of reviews in peer-reviewed journals:210
Number of publications (original work and reviews) in peer-reviewed journals:790
Cumulative IF for original publications in peer-reviewed journals:4196.39
Cumulative IF for reviews in peer-reviewed journals:1409.32
Cumulative IF of publications (original work & reviews) in peer-reviewed journals:5605.71
Total number of citations: 36,836, h-index: 99 (Web of Science December 2023)36836

Download-Information

To be able to download the offered contents, you have to login. If you do not know the login, please write me your request.